MedTrace Logo

Effect of Etomidate on Hemodynamics and Adrenocortical Function After Cardiac Surgery

NCT00415701 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 130

Last updated 2010-03-04

No results posted yet for this study

Summary

The purpose of this study is to evaluate the effect of a single dose of etomidate for patients undergoing cardiac surgery with the use of cardiopulmonary bypass (CPB) on post-CPB adrenocortical responsiveness, on requirements of hemodynamic support, and on use of intensive care resources.

Conditions

Interventions

DRUG

Etomidate

Single induction dose of etomidate 0.2%; total dose 0.15 mg/kg

DRUG

Propofol

Single induction dose of propofol 2%; total dose 1.5 mg/kg

DRUG

Hydrocortisone

Hydrocortisone 100 mg/2 ml: day of operation 3x, POD 1 2x, POD 2 1x

DRUG

NaCl 0.9%

NaCl 0.9% 2 ml; day of operation 3x, POD 1 2x, POD 2 1x

OTHER

Tetracosactin

Diagnostic test, Tetracosactin 250 microg iv

Sponsors & Collaborators

  • Insel Gruppe AG, University Hospital Bern

    lead OTHER

Principal Investigators

  • Stephan M Jakob, Professor · Insel Gruppe AG, University Hospital Bern

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-11-30
Primary Completion
2009-12-31
Completion
2009-12-31

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00415701 on ClinicalTrials.gov